Michael R. Page, PharmD, RPh | Authors


Case Shows Dramatic Antitumor Effects With Immunotherapy in Melanoma

July 23, 2015

A letter to the editor in the New England Journal of Medicine from notable researchers at Memorial Sloan Kettering reported a case of complete remission of metastatic melanoma in a patient treated with single doses of ipiliumab and nivolumab.

Epigenetic-Active Agents May Improve Sensitivity to Temozolomide in Melanoma

July 16, 2015

Using treatments that target epigenetic pathways, including the DNA methyltransferase inhibitor decitabine and the histone deacetylase (HDAC) inhibitor panobinostat, investigators hoped to improve the sensitivity of melanoma cells to the alkylating agent temozolomide.